Fibroblast growth factor–mediated crosstalk in cancer etiology and treatment

Abstract

It is becoming increasingly evident that multiple cell types within the tumor work together to drive tumour progression and impact on both the response to therapy and the dissemination of tumour cells throughout the body. Fibroblast growth factor signalling (FGF) is perturbed in a number of tumors, serving to drive tumor cell proliferation and migration, but also has a central role in orchestrating the plethora of cells that comprise the tumor microenvironment. This review focuses on how this family of signalling molecules can influence the interactions between tumor cells and their surrounding environment. Unraveling the complexities of FGF signalling between the distinct cell types of a tumor may identify additional opportunities for FGF-targeted compounds in therapy and could help combat drug resistance. Developmental Dynamics 246:493-501, 2017. © 2017 Wiley Periodicals, Inc.

The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives

“…Several reports have also highlighted the role of the FGF/FGFR system in the functional liaison between breast cancer cells and the surrounding tumor stroma [ 20 , 21 ]. Preclinical and clinical studies have indeed provided important hints on the feasibility of targeting FGFR in a novel anti-tumor strategy, at least in the subset of breast cancer patients harboring FGFR abnormalities [ 23 , 76 , 116 , 121 , 123 ].…”

“…Experimental and clinical evidence has also shown that deregulated FGF/FGFR signaling may elicit an oncogenic action [ 14 , 15 , 16 , 17 ], though some reports have indicated that the FGF/FGFR axis may exert an anticancer action in certain contexts [ 18 , 19 ]. Of note, various studies have emphasized the role of the transduction network triggered by the FGF/FGFR system towards a stimulatory interaction between tumor and stromal cells [ 20 , 21 ]. The aforementioned observations, together with the involvement of FGF/FGFR signaling in resistance to endocrine therapies [ 22 , 23 ], have suggested that the FGF/FGFR system may be considered a promising therapeutic target in order to establish more comprehensive anti-cancer strategies.…”

Integrated Analysis of Transcriptome and Prognosis Data Identifies FGF22 as a Prognostic Marker of Lung Adenocarcinoma

“…The FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth, and invasion. 27 The receptor of FGF22 is FGFR2b, which is encoded by the FGFR2 gene. Gene amplification or missense mutation of FGFR2 occurs in lung cancer, gastric cancer, breast cancer, and other cancers.…”

Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: a quantitative phosphoproteomics study

“…Many forms of cancer involve manifestations of aberrant FGFR signalling 8 . The activity of FGF ligands regulates tumour/stromal cell interactions such as angiogenesis, metastasis and immune evasion 2,9 . It has become increasingly clear, from genomic sequencing studies, that mutation of FGFRs is a prominent feature of diverse common cancer types 10 .…”